Last reviewed · How we verify
fosamprenavir (GW433908)
Fosamprenavir is a prodrug that is metabolized into amprenavir, a protease inhibitor.
Fosamprenavir is a prodrug that is metabolized into amprenavir, a protease inhibitor. Used for Treatment of HIV-1 infection in adults and children, Prevention of HIV-1 infection in adults and children.
At a glance
| Generic name | fosamprenavir (GW433908) |
|---|---|
| Sponsor | ViiV Healthcare |
| Drug class | Protease inhibitor |
| Target | HIV protease |
| Modality | Small molecule |
| Therapeutic area | Infectious disease |
| Phase | Phase 3 |
Mechanism of action
Amprenavir works by inhibiting the protease enzyme, which is necessary for the replication of retroviruses such as HIV. By blocking this enzyme, amprenavir prevents the virus from replicating and reduces the viral load in the body.
Approved indications
- Treatment of HIV-1 infection in adults and children
- Prevention of HIV-1 infection in adults and children
Common side effects
- Diarrhea
- Nausea
- Fatigue
- Headache
- Abdominal pain
Key clinical trials
- Fosamprenavir for Laryngopharyngeal Upper Airway Tissue Treatment and Enzyme Reduction (PHASE2)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
- Oral Fosamprenavir + Sodium Alginate for GERD (PHASE2)
- Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects (PHASE2)
- Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People (NA)
- Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- fosamprenavir (GW433908) CI brief — competitive landscape report
- fosamprenavir (GW433908) updates RSS · CI watch RSS
- ViiV Healthcare portfolio CI